Endocrinology, Vol 136, 5561-5569, Copyright © 1995 by Endocrine Society

ARTICLES

LLC-PK1 cells model 11 beta-hydroxysteroid dehydrogenase type 2 regulation of glucocorticoid access to renal mineralocorticoid receptors

C Leckie, KE Chapman, CR Edwards and JR Seckl
Molecular Endocrinology Laboratory, University of Edinburgh, Scotland, United Kingdom.

Mineralocorticoid receptors (MRs) are nonselective in vitro, binding corticosterone, cortisol, and aldosterone with similar affinity. In the distal nephron in vivo, MRs are selectively activated by aldosterone despite much higher glucocorticoid levels. This has been suggested to reflect the action of 11 beta-hydroxysteroid dehydrogenase (11 beta- HSD), which catalyzes rapid inactivation of corticosterone to 11- dehydrocorticosterone (cortisol to cortisone). However, cellular models of this effect have not been reported, and a recent study suggested that properties intrinsic to MR contribute to aldosterone selectivity. We have screened clonal mammalian cell lines for 11 beta-HSD activity. Pig kidney epithelial LLC-PK1 cells expressed by far the greatest 11 beta-HSD activity. In cell homogenates, this was NAD-dependent, with Km for corticosterone of 34.4 nM and cortisol of 89.7 nM. Intact LLC-PK1 cells showed similar apparent Km for corticosterone (13.9 nM) and cortisol (79.4 nM); only 11 beta-dehydrogenation was detected. These biochemical data indicate the expression of the type 2 isoform, 11 beta- HSD2. Using primers to conserved regions of 11 beta-HSD2, a reverse transcriptase-polymerase chain reaction product was obtained from LLC- PK1 cell RNA. Sequence analysis revealed close homology to previously cloned 11 beta-HSD2 cDNAs from several species. LLC-PK1 cell 11 beta- HSD activity was inhibited by carbenoxolone (IC50 approximately 10(-8) M) and high concentrations of estradiol or progesterone (10(-7) and 10(- 6) M), but was induced at lower estradiol concentrations (10(-8) and 10(-9) M). To examine whether the 11 beta-HSD2 activity in LLC-PK1 cells regulates corticosterone access to MR, cells were transfected with the corticosteroid-inducible mouse mammary tumor virus long terminal repeat-luciferase reporter construct. Cell transfection by a lipofection method did not alter 11 beta-HSD activity in LLC-PK1 cells. LLC-PK1 cells expressed low levels of MR (13.9 fmol/mg protein, dissociation constant (Kd) 0.3 x 10(-9) M for aldosterone) and glucocorticoid receptors (GR; 18.5 fmol/mg protein, Kd 0.3 x 10(-9) M for dexamethasone). Transfection with mouse mammary tumor virus long terminal repeat-luciferase reporter construct alone suggested that the endogenous levels of MR and GR were insufficient to affect transcription. However, cotransfection of LLC-PK1 cells with pRShMR, an MR expression plasmid, allowed at least 50-fold induction of luciferase with 10(-8) M aldosterone; the ED50 0.3 x 10(-9) M closely reflects the in vitro affinity of MR for aldosterone. Corticosterone only weakly induced luciferase (maximum of 6-fold induction).(ABSTRACT TRUNCATED AT 400 WORDS)

This article has been cited by other articles:

				E. P. Gomez-Sanchez, D. G. Romero, A. F. de Rodriguez, M. P. Warden, Z. Krozowski, and C. E. Gomez-Sanchez Hexose-6-Phosphate Dehydrogenase and 11{beta}-Hydroxysteroid Dehydrogenase-1 Tissue Distribution in the Rat Endocrinology, February 1, 2008; 149(2): 525 - 533. [Abstract] [Full Text] [PDF]

				D. Qi and B. Rodrigues Glucocorticoids produce whole body insulin resistance with changes in cardiac metabolism Am J Physiol Endocrinol Metab, March 1, 2007; 292(3): E654 - E667. [Abstract] [Full Text] [PDF]

				R. W. Carlin, R. L. Sedlacek, R. R. Quesnell, F. Pierucci-Alves, D. M. Grieger, and B. D. Schultz PVD9902, a porcine vas deferens epithelial cell line that exhibits neurotransmitter-stimulated anion secretion and expresses numerous HCO3- transporters Am J Physiol Cell Physiol, June 1, 2006; 290(6): C1560 - C1571. [Abstract] [Full Text] [PDF]

				C. Martin, M. Ross, K. E. Chapman, R. Andrew, P. Bollina, J. R. Seckl, and F. K. Habib CYP7B Generates a Selective Estrogen Receptor {beta} Agonist in Human Prostate J. Clin. Endocrinol. Metab., June 1, 2004; 89(6): 2928 - 2935. [Abstract] [Full Text] [PDF]

				S. Diederich, E. Eigendorff, P. Burkhardt, M. Quinkler, C. Bumke-Vogt, M. Rochel, D. Seidelmann, P. Esperling, W. Oelkers, and V. Bahr 11{beta}-Hydroxysteroid Dehydrogenase Types 1 and 2: An Important Pharmacokinetic Determinant for the Activity of Synthetic Mineralo- and Glucocorticoids J. Clin. Endocrinol. Metab., December 1, 2002; 87(12): 5695 - 5701. [Abstract] [Full Text] [PDF]

				S. Sarkar, S.-W. Tsai, T. T. Nguyen, M. Plevyak, J. F. Padbury, and L. P. Rubin Inhibition of placental 11beta -hydroxysteroid dehydrogenase type 2 by catecholamines via alpha -adrenergic signaling Am J Physiol Regulatory Integrative Comp Physiol, December 1, 2001; 281(6): R1966 - R1974. [Abstract] [Full Text] [PDF]

				P. Ferrari, A. Sansonnens, B. Dick, and F. J. Frey In Vivo 11{beta}-HSD-2 Activity: Variability, Salt-Sensitivity, and Effect of Licorice Hypertension, December 1, 2001; 38(6): 1330 - 1336. [Abstract] [Full Text] [PDF]

				A. M. Karssen, O. C. Meijer, I. C. J. van der Sandt, P. J. Lucassen, E. C. M. de Lange, A. G. de Boer, and E. R. de Kloet Multidrug Resistance P-Glycoprotein Hampers the Access of Cortisol But Not of Corticosterone to Mouse and Human Brain Endocrinology, June 1, 2001; 142(6): 2686 - 2694. [Abstract] [Full Text] [PDF]

				C.-B. Lanz, M. Causevic, C. Heiniger, F. J. Frey, B. M. Frey, and M. G. Mohaupt Fluid Shear Stress Reduces 11{beta}-Hydroxysteroid Dehydrogenase Type 2 Hypertension, January 1, 2001; 37(1): 160 - 169. [Abstract] [Full Text] [PDF]

				J. Stokes, J. Noble, L. Brett, C. Phillips, J. R. Seckl, C. O’Brien, and R. Andrew Distribution of Glucocorticoid and Mineralocorticoid Receptors and 11{beta}-Hydroxysteroid Dehydrogenases in Human and Rat Ocular Tissues Invest. Ophthalmol. Vis. Sci., June 1, 2000; 41(7): 1629 - 1638. [Abstract] [Full Text]

				S. A. Lloyd-MacGilp, S. M. Nelson, M. Florin, M. Lo, J. McKinnell, J. Sassard, and C. J. Kenyon 11{beta}-Hydroxysteroid Dehydrogenase and Corticosteroid Action in Lyon Hypertensive Rats Hypertension, November 1, 1999; 34(5): 1123 - 1128. [Abstract] [Full Text] [PDF]

				B. J. Waddell, R. Benediktsson, R. W. Brown, and J. R. Seckl Tissue-Specific Messenger Ribonucleic Acid Expression of 11{beta}-Hydroxysteroid Dehydrogenase Types 1 and 2 and the Glucocorticoid Receptor within Rat Placenta Suggests Exquisite Local Control of Glucocorticoid Action Endocrinology, April 1, 1998; 139(4): 1517 - 1523. [Abstract] [Full Text] [PDF]

				R. Diaz, R. W. Brown, and J. R. Seckl Distinct Ontogeny of Glucocorticoid and Mineralocorticoid Receptor and 11beta -Hydroxysteroid Dehydrogenase Types I and II mRNAs in the Fetal Rat Brain Suggest a Complex Control of Glucocorticoid Actions J. Neurosci., April 1, 1998; 18(7): 2570 - 2580. [Abstract] [Full Text] [PDF]

				R.-S. Ge, H.-B. Gao, V. L. Nacharaju, G. L. Gunsalus, and M. P. Hardy Identification of a Kinetically Distinct Activity of 11{beta}-Hydroxysteroid Dehydrogenase in Rat Leydig Cells Endocrinology, June 1, 1997; 138(6): 2435 - 2442. [Abstract] [Full Text] [PDF]

				S. S. Lim-Tio, M.-C. Keightley, and P. J. Fuller Determinants of Specificity of Transactivation by the Mineralocorticoid or Glucocorticoid Receptor Endocrinology, June 1, 1997; 138(6): 2537 - 2543. [Abstract] [Full Text] [PDF]

				P. C. White, T. Mune, and A. K. Agarwal 11{beta}-Hydroxysteroid Dehydrogenase and the Syndrome of Apparent Mineralocorticoid Excess Endocr. Rev., February 1, 1997; 18(1): 135 - 156. [Abstract] [Full Text]